Evogene to Participate in Upcoming BIO-Europe in Germany and Drug Discovery Chemistry Europe in Spain

Company to Attend BIO-Europe in Cologne, Germany, and Present a Scientific Poster at Drug Discovery Chemistry Europe in Barcelona, Spain

REHOVOT, Israel, Oct. 26, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), pioneering company in computational chemistry specializing in AI-based generative design of small molecules for the pharmaceutical and agricultural industries, today announced its participation in two upcoming industry conferences in Europe: BIO-Europe, to be held November 9-11, 2026, in Cologne, Germany, and Drug Discovery Chemistry Europe, to be held November 10-12, 2026, in Barcelona, Spain.

At BIO-Europe, Dr. Gabi Tarcic, Chief Development Officer, will represent Evogene and be available for one-on-one meetings with potential partners to discuss potential collaboration opportunities in AI-driven small-molecule discovery and development.

At Drug Discovery Chemistry Europe, Evogene will be represented by a delegation of executives leading the development of its technology platform and will present a scientific poster showcasing its ChemPass AI™ platform, which deploys proprietary AI across virtual screening, QSAR-driven hit-to-lead, and advanced generative de novo design to accelerate the discovery and optimization of novel small molecules. The team looks forward to engaging with industry colleagues to explore strategic collaborations in developing breakthrough computational technologies.

Conference Details:

BIO-Europe 2026

• Date: November 9-11, 2026
• Location: Cologne, Germany
• Conference website: www.informaconnect.com/bioeurope/

Drug Discovery Chemistry Europe 2026

• Date: November 10–12, 2026
• Location: Barcelona, Spain
• Poster Session: ChemPass ^AI: An End-to-End Small Molecule Discovery Platform – From Virtual Screening to De Novo Molecular Design
• Conference website: www.drugdiscoverychemistry.com/europe/posters

Evogene welcomes opportunities to connect with pharmaceutical and biotechnology companies interested in exploring collaborative drug discovery programs leveraging its AI-driven computational chemistry capabilities. Interested parties are encouraged to contact Evogene's investor or public relations team. 

About Evogene Ltd.: 

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for drug development and ag chemical products.

At the core of its technology is ChemPass AI^™, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.

For more information, please visit www.evogene.com.

Forward-Looking Statements:  

This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may," "could," "expects," "hopes," "intends," "anticipates," "plans," "believes," "scheduled," "estimates," "demonstrates" or words of similar meaning. For example, Evogene uses forward-looking statements in this press release when it discusses ChemPass AI™ as an enabler of new opportunities for collaborative drug discovery with pharmaceutical and biotech partners and as an accelerator for the discovery and optimization of novel small molecules for drug development. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the aftermath of the recent war between Israel and each of (i) the terrorist groups, Hamas and Hezbollah, (ii) Iran, and (iii) other regional terrorist groups supported by Iran, and any potential destabilizations in Israel, neighboring territories or the Middle East region, and those risk factors contained in Evogene's reports filed with the applicable securities authority. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

Contact

[email protected]
Tel: +972-8-9311901

SOURCE Evogene